Logo image of FULC

FULCRUM THERAPEUTICS INC (FULC) Stock Fundamental Analysis

USA - NASDAQ:FULC - US3596161097 - Common Stock

9.22 USD
-0.29 (-3.05%)
Last: 10/3/2025, 8:00:01 PM
9.22 USD
0 (0%)
After Hours: 10/3/2025, 8:00:01 PM
Fundamental Rating

4

Taking everything into account, FULC scores 4 out of 10 in our fundamental rating. FULC was compared to 197 industry peers in the Pharmaceuticals industry. While FULC has a great health rating, there are worries on its profitability. FULC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FULC has reported negative net income.
FULC had a negative operating cash flow in the past year.
In the past 5 years FULC always reported negative net income.
FULC had a negative operating cash flow in each of the past 5 years.
FULC Yearly Net Income VS EBIT VS OCF VS FCFFULC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

FULC's Return On Assets of -4.25% is fine compared to the rest of the industry. FULC outperforms 71.57% of its industry peers.
The Return On Equity of FULC (-4.54%) is better than 77.16% of its industry peers.
Industry RankSector Rank
ROA -4.25%
ROE -4.54%
ROIC N/A
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
FULC Yearly ROA, ROE, ROICFULC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

FULC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FULC Yearly Profit, Operating, Gross MarginsFULC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

9

2. Health

2.1 Basic Checks

FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FULC has been reduced compared to 1 year ago.
The number of shares outstanding for FULC has been increased compared to 5 years ago.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FULC Yearly Shares OutstandingFULC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
FULC Yearly Total Debt VS Total AssetsFULC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 18.47 indicates that FULC is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 18.47, FULC belongs to the top of the industry, outperforming 90.36% of the companies in the same industry.
There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.47
ROIC/WACCN/A
WACC9.86%
FULC Yearly LT Debt VS Equity VS FCFFULC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 24.42 indicates that FULC has no problem at all paying its short term obligations.
FULC's Current ratio of 24.42 is amongst the best of the industry. FULC outperforms 94.42% of its industry peers.
A Quick Ratio of 24.42 indicates that FULC has no problem at all paying its short term obligations.
The Quick ratio of FULC (24.42) is better than 94.92% of its industry peers.
Industry RankSector Rank
Current Ratio 24.42
Quick Ratio 24.42
FULC Yearly Current Assets VS Current LiabilitesFULC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for FULC have decreased strongly by -248.57% in the last year.
FULC shows a strong growth in Revenue. In the last year, the Revenue has grown by 2752.05%.
The Revenue has been growing by 61.03% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-248.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.18%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

FULC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.59% yearly.
The Revenue is expected to decrease by -9.72% on average over the next years.
EPS Next Y-430.28%
EPS Next 2Y-135.14%
EPS Next 3Y-68.07%
EPS Next 5Y-21.59%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-9.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
FULC Yearly Revenue VS EstimatesFULC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
FULC Yearly EPS VS EstimatesFULC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FULC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FULC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FULC Price Earnings VS Forward Price EarningsFULC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FULC Per share dataFULC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A cheap valuation may be justified as FULC's earnings are expected to decrease with -68.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-135.14%
EPS Next 3Y-68.07%

More info and screens

0

5. Dividend

5.1 Amount

FULC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (10/3/2025, 8:00:01 PM)

After market: 9.22 0 (0%)

9.22

-0.29 (-3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-29 2025-07-29/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners101.13%
Inst Owner Change6.28%
Ins Owners0.63%
Ins Owner Change-0.01%
Market Cap498.71M
Analysts80
Price Target11.29 (22.45%)
Short Float %6.94%
Short Ratio5.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.99%
Min EPS beat(2)5.34%
Max EPS beat(2)6.63%
EPS beat(4)4
Avg EPS beat(4)8.2%
Min EPS beat(4)5.34%
Max EPS beat(4)15.39%
EPS beat(8)8
Avg EPS beat(8)872.5%
EPS beat(12)11
Avg EPS beat(12)585.52%
EPS beat(16)13
Avg EPS beat(16)439.89%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)46.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.98%
EPS NY rev (1m)0%
EPS NY rev (3m)1.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.23
P/FCF N/A
P/OCF N/A
P/B 2.33
P/tB 2.33
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-1.22
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.2
OCFYN/A
SpS1.48
BVpS3.96
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.25%
ROE -4.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.99%
ROA(5y)-35.8%
ROE(3y)-33.54%
ROE(5y)-42.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.95%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.42
Quick Ratio 24.42
Altman-Z 18.47
F-Score5
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)40.72%
Cap/Depr(5y)49.27%
Cap/Sales(3y)16.46%
Cap/Sales(5y)14.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-248.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-132.18%
EPS Next Y-430.28%
EPS Next 2Y-135.14%
EPS Next 3Y-68.07%
EPS Next 5Y-21.59%
Revenue 1Y (TTM)2752.05%
Revenue growth 3Y61.03%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-9.72%
EBIT growth 1Y82.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-223.85%
EBIT Next 3Y-40.78%
EBIT Next 5YN/A
FCF growth 1Y30.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.81%
OCF growth 3YN/A
OCF growth 5YN/A